Start here if you're new
what it is
Kodiak develops retina drugs meant to prevent blindness, and it still has $0 TTM revenue.
how it gets paid
Last year Kodiak Sciences made n/a in revenue. KSI-301 program was the main engine at $0M, or 40% of sales.
what just happened
Kodiak lost $0.83 a share in Q4 2024, and the full-year loss narrowed to $3.35.
At a glance
C++ balance sheet — some cracks in the foundation
50/100 earnings predictability — expect surprises
-$3.35 fy2024 eps est
1.9 beta
~$1B market cap
xvary composite: 49/100 — below average
What they do
Kodiak develops retina drugs meant to prevent blindness, and it still has $0 TTM revenue.
You are buying 3 Phase 3 programs and 113 employees. That is a tiny team carrying a huge betting slip. The ABC Platform links antibody and chemistry work into one lab engine, so leaving means starting over.
How they make money
n/a
annual revenue
KSI-301 program
$0M
KSI-501 program
$0M
KSI-101 program
$0M
ABC Platform
$0M
The products that matter
lead retinal drug candidate
Tarcocimab
single lead program
This is the asset doing almost all of the narrative work. If it produces convincing clinical data, the valuation framework changes from cash burn to commercial probability. If it does not, the stock stops pretending to be a pipeline.
the story
balance sheet runway
Cash and financing capacity
$150M debt on the books
For a pre-revenue biotech, financing is part of the product. The page gives you $150M of long-term debt and a C++ balance sheet grade. That means runway matters as much as science from here.
survival
pipeline optionality
Platform follow-ons
thin public detail
Management can say this is bigger than one asset. The page does not give enough hard data to underwrite that claim. Until more shows up, you should treat optionality as upside, not as the base case.
maybe later
Key numbers
C++
Balance sheet
C++ means decent, not deluxe. With $150M of long-term debt and $0 TTM revenue, you care about the next trial.
1.9
Beta
1.9 means the stock has moved about twice the market. Your position can swing harder than the headlines.
$150M
Long-term debt
Debt is real while sales are not. That is a rough combo for a precommercial biotech.
$3.35
FY24 EPS est
The loss estimate says the business is still burning cash. No sales makes every quarter count.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $150M (10% of capital)
C++ — risk rank looks solid but balance sheet grade needs watching.
Total return vs. market
Return history isn't available for KOD right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Kodiak lost $0.83 a share in Q4 2024, and the full-year loss narrowed to $3.35.
Q4 EPS improved from -$1.35 a year earlier to -$0.83. Full-year EPS improved from -$4.97 in 2023 to -$3.35 in 2024.
$0.83
q4 eps
$3.35
fy24 eps
$1.35
q4 2023 eps
Q4 EPS
The -$0.83 quarterly loss matters because it is better than -$1.35 a year ago, but it is still a loss with $0 TTM revenue.
source: and Yahoo Finance consensus, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The biggest risk is specific and boring: tarcocimab does not deliver convincing retinal data. When a pre-revenue biotech has one lead program, science is the balance sheet.
med
lead trial data disappoints
If tarcocimab misses on efficacy, durability, safety, or simply fails to look differentiated enough, the core valuation case breaks. There is no diversified revenue base here to cushion that.
This would pressure the entire ~$1B equity story because the company has no revenue and one lead asset doing the heavy lifting.
med
cash burn turns into dilution
Losses of -$4.12 per share over the last four quarters and a C++ balance sheet tell you the company still needs capital discipline. If timelines slip, new money usually arrives on terms existing holders do not enjoy.
That risk is amplified by $150M of long-term debt and the absence of operating revenue.
med
the market is real, but so is the incumbent
Roche's Vabysmo is expected to do about $5.3B in 2025 sales. That proves retinal disease is commercially attractive. It also means Kodiak is not entering an empty field. Good science may still need to be clearly better science.
Commercial upside can compress even if the program works, especially if differentiation looks thin.
A failed dataset hurts. A delayed dataset with a financing need can hurt almost as much. That is the math of single-asset biotech.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next clinical or corporate update
With no revenue base to analyze, the next scheduled update matters because it tells you whether the timetable is holding or slipping.
trend
whether tarcocimab becomes a program or stays a promise
This is the whole page in one line. Progress that tightens the path to commercialization changes the valuation framework. More waiting does not.
risk
balance sheet pressure
A C++ balance sheet and $150M of long-term debt mean financing risk is always nearby. Watch for signs that time is getting more expensive.
metric
price stability: 5/100
That number is the market's warning label. If you own this, you are owning event risk with a ticker symbol.
Analyst rankings
short-term outlook
mixed
Target data is thin here. In human-speak, analysts do not have a clean consensus because the next dataset matters more than the spreadsheet.
risk profile
volatile
A 1.9 beta and 5/100 price stability translate to bigger swings than the average stock. This is normal for small-cap biotech. It is still painful when you are on the wrong side of it.
chart momentum
catalyst-driven
The stock traded between $2 and $31 in the last 52 weeks. That is not smooth momentum. That is event sensitivity.
earnings predictability
50/100
Predictability: 50/100. In plain English, quarterly numbers are not giving you much certainty because there is no mature operating model yet.
source: institutional data
Institutional activity
institutional ownership data for KOD is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$24
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive